/Companies

Mesenbio

3 known investors

Find your way into Mesenbio

Sign up to see every warm intro you have to Mesenbio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Mesenbio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.

Founders & leadership

DDDr. David Kuntin
Dr. David KuntinChief Executive Officer
PP
Prof. Paul GeneverChief Scientific Officer
AAAnita Adams
Anita AdamsFinance DirectorAnita Adams is a fractional Finance Director with over 30 years of accounting experience, including 25 years in senior and executive roles, specializing in fund-raising, financial restructuring, and high-growth businesses.

Board

DDDr. David Simpson
Dr. David SimpsonChair
JGJason Goldstein
Jason GoldsteinBoard director

Investors · 3

Also in the syndicate · 1

NG Bio

In the news

Frequently asked questions

What does Mesenbio do?
Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.
Who are Mesenbio's investors?
Mesenbio's investors include DSW Ventures, Innovate UK.